Planta Med 2008; 74 - PB37
DOI: 10.1055/s-0028-1084382

Flavan-3-ols from the roots of Actinidia arguta inhibit the formation of advanced glycation end products (AGEs) in vitro

GY Lee 1, DS Jang 1, JL Yoo 1, YM Lee 1, YS Kim 1, JS Kim 1
  • 1Department of Herbal Pharmaceutical Development, Korea Institute of Oriental Medicine, 461–24 Jeonmin-dong, Yuseong-gu, Daejeon 305–811, Republic of Korea

In an ongoing project directed toward the discovery of novel treatments for diabetic complications from traditional herbal medicines [1–3], two new flavan-3-ols, 8-(2-pyrrolidinone-5-yl)-(–)-epicatechin (1) and 6-(2-pyrrolidinone-5-yl)-(–)-epicatechin (2), as well as five known compounds, (–)-epicatechin (3), (+)-catechin (4), proanthocyanidin B-4 (5), (+)-pinoresinol (6), and p-hydroxybenzoic acid (7), were isolated from an EtOAc-soluble extract of the roots of Actinidia arguta. The structures of compounds 1 and 2 were elucidated by spectroscopic data interpretation, particularly by extensive 1D and 2D NMR studies. All the isolates were evaluated in vitro for inhibitory activity on the formation of advanced glycation end products (AGEs). Of these, compounds 1-5 exhibited significant AGEs formation inhibitory activity with IC50 values ranging from 10.1 to 125.2µM.

Acknowledgements: This research was supported by a grant [L07010] from the Korea Institute of Oriental Medicine.

References: 1. Jang, D.S., et al. (2006) Chem. Pharm. Bull. 54: 1315–1317. 2. Lee, G.Y., et al. (2006) Arch. Pharm. Res. 29: 587–590. 3. Jang, D.S., et al. (2007) Biol. Pharm. Bull. 30: 2207–2210.